Cancer cachexia is known to adversely affect the clinical course in patients with malignant lymphoma. The cachexia index (CXI) is a potential biomarker of cancer cachexia, and its implications for the prognosis and treatment outcome of lung cancer and aggressive lymphoma has been assessed in previous studies.

中文翻译：

---

恶病质指数作为癌症恶病质的潜在生物标志物和弥漫性大 B 细胞淋巴瘤的预后指标

已知癌症恶病质会对恶性淋巴瘤患者的临床过程产生不利影响。恶病质指数（CXI）是癌症恶病质的潜在生物标志物，其对肺癌和侵袭性淋巴瘤的预后和治疗结果的影响已在先前的研究中进行了评估。